124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
June 2023 in “Research Square (Research Square)” Sky Fruit Seed Crush can preserve goatskin with less environmental impact than traditional methods.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
1 citations,
October 2023 in “Clinical, cosmetic and investigational dermatology” Traditional treatment for pediatric alopecia areata is most effective and should be first choice.
4 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
April 2024 in “Dermatology and therapy” There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
4 citations,
January 2022 in “Drug design, development and therapy” Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.
3 citations,
April 2019 in “Journal of Dermatological Treatment” Caffeine shows promise for treating some types of hair loss, but more research is needed.
1 citations,
January 2023 in “Burns and trauma” Tiny particles from 3D-grown skin cells speed up wound healing by promoting blood vessel growth.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
1 citations,
October 2022 in “International Journal of Molecular Sciences” Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.
40 citations,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
14 citations,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
60 citations,
July 2014 in “Autophagy” The protein FLCN is involved in cellular cleanup and is regulated by ULK1.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
1 citations,
January 2024 CaBP1 and CaBP2 are necessary for proper hearing and neurotransmission in the ear's inner hair cells.
CaBP1 and CaBP2 are necessary for proper hearing and neurotransmission in the ear's inner hair cells.
CaBP1 and 2 are important for maintaining the activity of calcium channels necessary for hearing in inner ear cells.
January 2024 in “Medicine” Hypothyroidism is often linked to the hair loss condition telogen effluvium.